Sclerotheraphy with OK-432 for the Treatment of Lymphangiomas.
- Author:
Young Gwon WANG
1
;
Hyung Il SEO
;
Hae Young KIM
Author Information
1. Department of Surgery, College of Medicine, Pusan National University, Busan, Korea. drking-md@hanmail.net
- Publication Type:Original Article
- Keywords:
Lymphangioma;
OK-432;
Cystic hygroma
- MeSH:
Humans;
Injections, Intralesional;
Lymphangioma*;
Lymphangioma, Cystic;
Picibanil*;
Retrospective Studies;
Sclerotherapy
- From:Cancer Research and Treatment
2002;34(1):62-66
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the efficacy of sclerotherapy with OK-432 for lymphangiomas. MATERIALS AND METHODS: Retrospective review of twelve patients with lymphangiomas who were treated with OK-432 from 1996 to 2000. RESULTS: Twelve patients were treated by sclerotherapy with OK-432. Ten patients were received sclerotherapy with OK-432 as primary therapy, and two were treated as secondary therapy after failure of surgery. Six cases were cystic hygroma (macrocystic); all of them, complete shrinkage was obtained. The other six cases were cavernous lymphangioma (microcystic): two of them, therapy were successful, but four were failed to achieve satisfactory shrinkage. So, they underwent surgical excision after failure of sclerotherapy. The results were excellent in cystic hygroma (success rate; 100%), however moderately poor results were obtained in cavernous lymphangioma (success rate 33.3%). CONCLUSION: Intralesional injection of OK-432 is effective therapy for cystic hygroma as a primary therapy.
